HOLDINGS

AELAN CELL TECHNOLOGIES
Diagnostic/Cell Therapy

Aelan Cell Technologies is a biomedical innovation company focused on the research, development, and commercialization of advanced healthcare technologies designed to improve human health, longevity, and disease management. Founded in 2015 and headquartered in San Francisco, California, the company operates at the intersection of molecular diagnostics, regenerative medicine, precision healthcare, and aging science. Led by a multidisciplinary team of scientists and business leaders under the direction of renowned stem cell researcher Dr. Victoria Lunyak, Aelan is building an integrated biotechnology platform designed to address some of the largest and fastest growing healthcare markets in the world.

The company is strategically focused on two major sectors with enormous global commercial potential: Molecular Diagnostics and Cell Therapy. Together, these sectors represent $100 Billion+ market opportunities that are rapidly expanding as healthcare transitions toward precision medicine, preventative care, biologics, and regenerative therapeutics. Global healthcare systems, pharmaceutical companies, and institutional investors are increasingly prioritizing technologies capable of enabling earlier disease detection, personalized treatment strategies, and tissue regeneration, creating unprecedented demand for next generation biomedical platforms.

Aelan’s Molecular Diagnostics division is focused on developing innovative biomarker driven technologies designed to enable earlier disease detection, patient stratification, disease monitoring, and therapeutic optimization. The company’s scientific approach integrates epigenetics, proteomics, stem cell biology, and molecular analytics to identify biological signatures associated with aging and chronic disease progression. Aelan is particularly focused on large unmet medical needs within neurodegenerative disease, oncology, regenerative medicine, and age related disorders where earlier and more accurate diagnostics can dramatically improve patient outcomes while reducing long term healthcare costs.

The global in vitro diagnostics and molecular diagnostics markets represent one of the largest and most strategically important sectors in healthcare. The worldwide diagnostics market is projected to surpass $150 Billion annually over the coming years, while the molecular diagnostics segment alone is expected to grow into a $25 Billion+ market as precision medicine and biomarker based testing become standard components of clinical care. In parallel, the companion diagnostics market continues to expand rapidly as pharmaceutical companies increasingly require biomarker driven patient selection tools to support targeted therapies, immunotherapies, and next generation drug development programs.

These trends are driving significant merger and acquisition activity across the diagnostics landscape as large healthcare companies aggressively seek innovative platforms with strong intellectual property and scalable clinical applications.
Aelan’s second core business area, Cell Therapy and Regenerative Medicine, is focused on leveraging advanced stem cell biology and cellular aging research to support the future development of regenerative therapeutics and next generation biomedical applications. The company’s scientific foundation is rooted in understanding the mechanisms of cellular vitality, tissue regeneration, and biological aging, areas widely considered among the most important frontiers in modern medicine. By integrating regenerative biology with molecular analytics and biomarker discovery, Aelan is positioning itself within a transformational sector that has attracted billions of dollars in global investment from pharmaceutical companies, sovereign wealth funds, and institutional capital.

The global regenerative medicine and cell therapy markets are projected to grow into $100 Billion+ to $300 Billion+ opportunities over time as new therapies continue moving through clinical development and commercialization. Cell therapy alone is widely expected to become one of the defining categories of twenty first century medicine, with applications spanning oncology, neurodegenerative disease, autoimmune disorders, cardiovascular disease, tissue engineering, and healthy aging. The emergence of advanced biologics, stem cell therapies, gene editing technologies, and personalized regenerative treatments has created one of the most dynamic and valuable investment landscapes in biotechnology today.

Aelan’s long term strategy centers on building a strong intellectual property portfolio, advancing translational research, establishing strategic partnerships, and developing scalable commercialization pathways across both diagnostics and regenerative medicine. The company’s integrated platform is designed to create defensible competitive advantages while supporting future collaborations with pharmaceutical companies, healthcare systems, research institutions, and global industry leaders seeking access to innovative biomedical technologies.

With growing global demand for precision healthcare, early disease detection, longevity science, and regenerative therapeutics, Aelan Cell Technologies is building a platform designed to participate in some of the most significant healthcare and biotechnology opportunities of the modern era. Through its combination of scientific innovation, multidisciplinary expertise, and strategic market positioning, Aelan is focused on creating long term value across two of the most transformative sectors in global healthcare.